You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Mallinckrodt
McKesson
Merck
Medtronic

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

Claims for Patent: 7,838,239

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,838,239
Title:Methods regarding enhanced T-cell receptor-mediated tumor necrosis factor superfamily mRNA expression in peripheral blood leukocytes in patients with crohn\'s disease
Abstract: A method is disclosed for determining whether a human having Crohn\'s disease is likely to respond to a therapy targeting a TNFSF member or a cytokine by measuring the level of certain mRNAs in response to a stimulus. A method of evaluating the effectiveness of a Crohn\'s disease therapy in a human is also disclosed. Furthermore, a method of screening compounds for use in the treatment of Crohn\'s disease is disclosed. A method of monitoring the disease state over time in Crohn\'s disease patients is also disclosed.
Inventor(s): Mitsuhashi; Masato (Irvine, CA), Targan; Stephan R. (Santa Monica, CA)
Assignee: Hitachi Chemical Co., Ltd. (Tokyo, JP) Hitachi Chemical Research Center, Inc. (Irvine, CA) Cedars-Sinai Medical Center (Los Angeles, CA)
Application Number:12/296,425
Patent Claims:1. A method of determining whether a human having Crohn's disease is likely to respond to immunosuppressive therapy, comprising: stimulating leukocytes with an anti-T-cell receptor antibody in vitro in a first sample that comprises leukocytes from the human; after the stimulation, measuring the amount of an mRNA encoding a tumor necrosis factor superfamily member in the first sample; exposing leukocytes in vitro in a second sample comprising leukocytes from the human to a control stimulus; measuring the amount of the mRNA in the second sample after exposing; and determining a ratio of the amount of the mRNA in the first sample to the amount of the mRNA in the second sample, wherein a ratio of at least about 1.7:1 indicates that the human is likely to respond to said immunosuppressive therapy.

2. The method of claim 1, wherein at least one of the first and second samples comprises whole blood.

3. The method of claim 1, wherein the control stimulus comprises a purified control immunoglobulin.

4. The method of claim 1, wherein the therapy targets TNF-.alpha. activity.

5. The method of claim 4, wherein the therapy comprises administration of infliximab.

6. The method of claim 1, wherein the therapy comprises administration of an agent selected from the group consisting of cyclosporine A and tacrolimus.

7. A method of evaluating the state of Crohn's disease in a human, comprising: stimulating leukocytes with an anti-T-cell receptor antibody in vitro in a first sample that comprises leukocytes and is obtained at a first time from the human; after the stimulation, measuring the amount of an mRNA encoding a tumor necrosis factor superfamily member in the first sample; exposing leukocytes in vitro to a control stimulus in a second sample comprising leukocytes obtained from the human at the first time; measuring the amount of the mRNA in the second sample after exposing; determining a first ratio of the amount of the mRNA in the first sample to the amount of the mRNA in the second sample; stimulating leukocytes with an anti-T-cell receptor antibody in vitro in a third sample that comprises leukocytes and is obtained from the human at a second time that is subsequent to the first time; after the stimulation, measuring the amount of the mRNA in the third sample; exposing leukocytes in vitro to a control stimulus in a fourth sample comprising leukocytes obtained from the human at the second time; measuring the amount of the mRNA in the fourth sample after exposing; determining a second ratio of the amount of the mRNA in the third sample to the amount of the mRNA in the fourth sample; and comparing the first and second ratios, wherein a statistically significant difference in the first and second ratios is indicative of a change in the disease state.

8. The method of claim 7, wherein the control stimulus comprises a purified control immunoglobulin.

9. The method of claim 7, wherein at least one of the first, second, third and fourth samples comprises whole blood.

10. The method of claim 7, wherein the significant difference in the ratios is that the second ratio is greater than the first ratio, and the change in disease state is a progression of the disease.

11. The method of claim 7, wherein the significant difference in the ratios is that the first ratio is greater than the second ratio, and the change in disease state is a regression of the disease.

12. The method of any of claims 1 and 7 wherein the tumor necrosis factor superfamily ("TNFSF") member is selected from the group consisting of TNFSF-2, TNFSF-5, TNFSF-6, and TNFSF-14.

13. The method of claim 12, wherein the TNFSF member is selected from the group consisting of TNFSF-2 and TNFSF-14.

Summary for Patent:   Start Trial

PCT Information
PCT FiledApril 05, 2007PCT Application Number:PCT/US2007/008597
PCT Publication Date:October 18, 2007PCT Publication Number:WO2007/117611

Details for Patent 7,838,239

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial Hitachi Chemical Co., Ltd. (Tokyo, JP) Hitachi Chemical Research Center, Inc. (Irvine, CA) Cedars-Sinai Medical Center (Los Angeles, CA) 2026-04-07 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Express Scripts
Dow
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.